Trigeminal neuralgia has a reputation among clinicians for a reason. People describe it as electric, stabbing, lightning-like—a jolt of pain across the cheek, jaw, or around the eye that can be set off by something as ordinary as a breeze, brushing your teeth, or chewing. It’s sometimes called the “suicide disease,” an old and grim nickname that reflects how relentless and life-altering the pain can be when it isn’t controlled. We don’t use that phrase lightly, but it’s worth naming, because anyone living with this condition already knows how serious it is.

Most people who reach out to us about trigeminal neuralgia have already been through the standard treatments. They’ve tried carbamazepine or oxcarbazepine, maybe other medications, possibly a procedure. Some have found relief; others are sitting with pain that has outrun everything offered so far. That’s usually the point at which the question of ketamine comes up. This article is our honest attempt to explain what ketamine can and can’t reasonably offer here.

What Trigeminal Neuralgia Is

The trigeminal nerve is the fifth cranial nerve, and it carries sensation from the face to the brain across three branches—roughly the forehead and eye region, the cheek, and the lower jaw. In classic trigeminal neuralgia, the most common cause is a blood vessel pressing on the nerve where it exits the brainstem, irritating it and stripping away part of its protective coating over time. The result is a nerve that misfires, sending intense pain signals in response to light, normally harmless touch.

But the pain isn’t only about the nerve at the periphery. With time, repeated barrages of pain signaling can change how the central nervous system itself processes those signals. This is where ketamine’s mechanism becomes relevant.

Central Sensitization: The Part Ketamine Targets

When a pain pathway is fired repeatedly and intensely, neurons in the spinal cord and brainstem can become abnormally excitable. They start amplifying signals, responding to weaker inputs, and sometimes generating pain even without a clear trigger. Pain researchers call this central sensitization, and it’s a recurring feature across chronic pain conditions, not just trigeminal neuralgia.

At the molecular level, the NMDA receptor is one of the key players in establishing and sustaining central sensitization. It acts something like a gatekeeper for the long-term strengthening of pain signaling. Ketamine is an NMDA receptor antagonist—it blocks that receptor. The hypothesis, supported by the broader pain literature, is that by interrupting NMDA-driven signaling, ketamine can dampen central sensitization and, in some cases, help the nervous system step back from its hyper-amplified state.

This is the same logic behind ketamine’s use in other central pain conditions. We’ve written about it in the context of CRPS, fibromyalgia, and neuropathic pain more broadly. Trigeminal neuralgia sits within that same family of conditions where central amplification plays a role, which is part of why ketamine has drawn interest here.

Ketamine, an NMDA receptor antagonist, is hypothesized to reverse the central sensitization associated with the causation and propagation of craniofacial pain. Bolus ketamine treatment had an effect in reducing the intensity of trigeminal neuralgia. — Systematic review of ketamine for craniofacial pain, Canadian Journal of Pain, 2023

What the Research Actually Shows

Here’s the part where we have to be careful not to overpromise. The honest state of the evidence is: promising in mechanism, modest in volume, and still developing.

A 2023 systematic review published in the Canadian Journal of Pain examined ketamine for craniofacial pain and concluded that bolus ketamine had a measurable effect in reducing trigeminal neuralgia pain intensity. That’s a meaningful signal. But trigeminal neuralgia specifically has relatively little dedicated, high-quality trial data; much of what we know is extrapolated from broader nerve-pain and facial-pain research, and from smaller studies and case series.

Research is actively moving forward. Several clinical trials launched in 2025 and 2026 are studying esketamine—the S-enantiomer form of ketamine—combined with procedures like pulsed radiofrequency for trigeminal postherpetic neuralgia and zoster-associated facial nerve pain. These are related but distinct conditions, and the results aren’t in yet, but they reflect genuine clinical interest in ketamine’s role for difficult facial pain.

We’d be doing you a disservice if we left out the cautionary side. In 2024, the U.S. Department of Veterans Affairs classified ketamine for chronic pain as investigational and experimental, pointing to a lack of high-quality evidence on its safety and effectiveness for pain conditions generally. We don’t think that closes the door—plenty of useful treatments start in exactly this position—but it’s an accurate reflection of where the field stands. Ketamine for trigeminal neuralgia is a reasonable option to explore in the right circumstances, not a settled, proven cure.

Where Ketamine Fits—and Where It Doesn’t

This matters enough to state plainly: ketamine is not a replacement for first-line treatment. For trigeminal neuralgia, the anticonvulsant carbamazepine (and its relative oxcarbazepine) remains the standard first medication, and it works well for many people. When medications fail or aren’t tolerated, surgical options such as microvascular decompression—which relieves the pressure of the blood vessel on the nerve—or procedures like rhizotomy and gamma knife radiosurgery are established and often effective.

We see ketamine as something to consider when:

That last point is not a formality. Trigeminal neuralgia is best managed collaboratively, and we coordinate with the neurologist or specialist overseeing your care rather than operating off on our own. Ketamine is one tool, and it works better as part of a thought-out plan than as a standalone attempt to outrun the pain.

What Treatment Looks Like Here

If you come to us about trigeminal neuralgia, the first step is a real consultation, not a sales pitch. Marla, our CRNA with more than two decades of clinical experience, will review your diagnosis, any imaging, your current and past medications, the procedures you’ve had, and your overall health. Some people aren’t good candidates, and we’ll tell you honestly if we think ketamine isn’t the right fit—the same way we describe in our piece on when we decline ketamine for a patient.

If ketamine does appear reasonable, infusions are given intravenously in our clinic, monitored closely throughout. Protocols for pain often differ from those used for depression—dosing, infusion length, and the number of sessions are tailored to the situation rather than applied off a single template. For a sense of the setting and what an infusion is actually like, our article on what a ketamine infusion feels like walks through it. The environment is calm and unhurried, and yes, our therapy dogs Walter White and Wilma are usually around.

A Realistic, Compassionate Bottom Line

Living with trigeminal neuralgia can be isolating in a particular way—the pain is invisible, the triggers can seem trivial to others, and the fear of the next jolt shapes ordinary days. We don’t want to add false hope to that burden. Ketamine is not a guaranteed answer, and the evidence for it in trigeminal neuralgia is still being built.

What we can offer is an honest conversation grounded in the mechanism, the current research, and your specific history—and a clear-eyed assessment of whether it’s worth trying in your case. If standard treatments have left you with pain that won’t quit, and you’re looking for someone to think it through carefully with you rather than oversell a solution, we’re here for that.